Ten-Year Experience of Stereotactic Body Radiotherapy at a Single Institution: Impact of Technological Development on the Outcome of Patients With Early Lung Cancer

DOI Web Site Web Site PubMed 23 References Open Access
  • Keiichiro Koiwai
    Department of Radiology, Shinshu University, School of Medicine, Matsumoto, Japan
  • Yuuki Endo
    Department of Radiology, Shinshu University, School of Medicine, Matsumoto, Japan
  • Kai Mizuhata
    Department of Radiology, Shinshu University, School of Medicine, Matsumoto, Japan
  • Hironobu Ina
    Department of Radiology, Shinshu University, School of Medicine, Matsumoto, Japan
  • Ayumu Fukazawa
    Department of Radiology, Shinshu University, School of Medicine, Matsumoto, Japan
  • Takesumi Ozawa
    Department of Radiology, Shinshu University, School of Medicine, Matsumoto, Japan
  • Yasunari Fujinaga
    Department of Radiology, Shinshu University, School of Medicine, Matsumoto, Japan

Search this article

Description

<jats:sec><jats:title>Purpose:</jats:title><jats:p> Advanced radiotherapeutic techniques and apparatus have been developed and widely applied in stereotactic body radiation therapy for early-stage non-small cell lung cancer, but their clinical benefits have not necessarily been confirmed. This study was performed to review our 10-year experience with therapy for the disease and to evaluate whether the advanced radiotherapeutic system implemented in our hospital 5 years after we began the therapy improved the clinical outcomes of patients. </jats:p></jats:sec><jats:sec><jats:title>Materials and Methods:</jats:title><jats:p> Patients who underwent the therapy at our hospital between April 2008 and March 2018 were retrospectively reviewed. They were divided into 2 groups treated with the conventional system or the advanced system, and the characteristics and clinical outcomes were compared between the groups. The same analyses were also performed in propensity-matched patients from the 2 groups. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Among the 73 patients eligible for this study, 42 were treated with the conventional system and 31 with the advanced system. All were treated as planned, and severe adverse events were rare. The local progression-free survival rate in the advanced system group was significantly higher than in the conventional system group (P = 0.025). In the propensity-matched patients, both the local progression-free survival rate and the overall survival rate were significantly higher compared in the advanced system group than the conventional system group (P = 0.089 and 0.080, respectively). </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> The advanced system improved the outcomes of patients with the disease, suggesting that technological development has had a strong impact on clinical outcomes. </jats:p></jats:sec>

Journal

References(23)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top